ClinicalTrials.gg
RecruitingNCT06842355Updated Oct 1, 2026

A Study of TYRA-300 in Children With Achondroplasia: BEACH301

A Phase 2 interventional study of TYRA-300 0.125 mg/kg and TYRA-300 0.25 mg/kg in Achondroplasia, sponsored by Tyra Biosciences, Inc. Recruiting at 25 sites in 8 countries. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Tyra Biosciences, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 1, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Achondroplasia with a site in United States — 8 open to participants now, 11 under way, 3 of them phase 3. Achondroplasia · United States.

Planned enrollment
7th of 20
92 · median 76
Started
2025
with 1 other
Phase 2
12 of 29
4 open now
Primary completion
2030-01
later than 4 of 10 live
Registered
27th of 29
by date
Lead sponsor
1 of 29
Tyra Biosciences, Inc

Among the 29 studies in Achondroplasia with a site in United States, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 27th registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

8 of the 29 studies in Achondroplasia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Achondroplasia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.

Read the detailed description

This is a Phase 2, multicenter, open-label, dose-escalation study to determine the safety, tolerability, and identify potentially effective dose(s) of TYRA-300, a fibroblast growth factor receptor (FGFR)-3 selective tyrosine kinase inhibitor, in children 3 to 10 years of age with achondroplasia with open growth plates that will examine three cohorts of children: the Sentinel Safety Cohort, Cohort 1, and Cohort 2.

03

Conditions studied

  • Achondroplasia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 3 to 10 years old (inclusive) at the time of consent.
  • provided by parent(s) or legal guardian(s). As study participants are less than 18 years old, participants are willing and able to provide written assent (where applicable and required).
  • Molecular diagnosis of achondroplasia (FGFR3 G380R).
  • Radiographically confirmed open growth plates at Screening, as determined by bone age X-ray.
  • Able to stand and ambulate independently.
  • Able to take oral medication.
  • Sentinel Safety Cohort only: aged 5 to 10 years old (inclusive).
  • Cohort 1 only: aged 3 to 10 years old (inclusive) and are naive to prior growth accelerating therapy.
  • Cohort 2 only: aged 3 to 10 years old (inclusive) and have received prior growth accelerating therapy.

Exclusion criteria

Exclusion Criteria:

  • Presence or history of any concurrent disease or condition that would interfere with study participation, safety evaluations, or any uncontrolled or untreated condition that could impact pediatric growth.
  • Diagnosis of endocrine condition that alters calcium/phosphate homeostasis.
  • Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study.
  • Taking medications that are strong inhibitors or inducers of cytochrome P450 (Cyp) 3A4.
  • History or current evidence of corneal or retinal disorder/keratopathy.
  • Presence of guided growth hardware/8 plates. Planned or anticipated orthopedic surgeries.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    TYRA-300 0.125 mg/kg

    TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.

    Drug: TYRA-300 0.125 mg/kg

  • Experimental
    TYRA-300 0.25 mg/kg

    TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.

    Drug: TYRA-300 0.25 mg/kg

  • Experimental
    TYRA-300 0.375 mg/kg

    TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.

    Drug: TYRA-300 0.375 mg/kg

  • Experimental
    TYRA-300 0.50 mg/kg

    TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.

    Drug: TYRA-300 0.50 mg/kg

  • Experimental
    TYRA-300 0.625 mg/kg

    TYRA-300 is provided as sprinkle capsules/mini-tablets. The total dose will be calculated based on the participant's weight. Weight adjustments will be made every 3 months.

    Drug: TYRA-300 0.625 mg/kg

Interventions

  • DrugTYRA-300 0.125 mg/kg

    Drug page: Dabogratinib

    Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.

  • DrugTYRA-300 0.25 mg/kg

    Drug page: Dabogratinib

    Subsequent dose level escalations will occur based on criteria outlined in the protocol.

  • DrugTYRA-300 0.375 mg/kg

    Drug page: Dabogratinib

    Subsequent dose level escalations will occur based on criteria outlined in the protocol.

  • DrugTYRA-300 0.50 mg/kg

    Drug page: Dabogratinib

    Subsequent dose level escalations will occur based on criteria outlined in the protocol.

  • DrugTYRA-300 0.625 mg/kg

    Drug page: Dabogratinib

    Subsequent dose level escalations may occur based on criteria outlined in the protocol.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Up to 12 months

  2. Change from baseline in annualized growth velocity (Cohort 1)

    Time frame: 12 months

Secondary outcomes

  1. Change from baseline in annualized growth velocity (Cohort 1)

    Time frame: 6 months

  2. Change from baseline in height z-score (Cohort 1)

    Time frame: 6 and 12 months

  3. Pharmacokinetics: maximum plasma concentration (Cmax)

    Time frame: 15 days

  4. Pharmacokinetics: time to reach maximum plasma concentration (Tmax)

    Time frame: 15 days

  5. Pharmacokinetics: area under the plasma concentration-time curve (AUC)

    Time frame: 15 days

  6. Pharmacokinetics: half-life of TYRA-300 (t1/2)

    Time frame: 15 days

  7. Pharmacokinetics: apparent total clearance (CL/F)

    Time frame: 15 days

  8. Pharmacokinetics: apparent volume of distribution (Vd/F)

    Time frame: 15 days

  9. Change from baseline in annualized growth velocity (Cohort 2)

    Time frame: 6 and 12 months

  10. Change from baseline in height z-score (Cohort 2)

    Time frame: 6 and 12 months

  11. Change from baseline in standing height (cm)

    Time frame: 6 and 12 months

  12. Change from baseline in sitting height (cm)

    Time frame: 6 and 12 months

  13. Change from baseline in upper and lower arm length (cm)

    Time frame: 6 and 12 months

  14. Change from baseline in tibial length (cm)

    Time frame: 6 and 12 months

  15. Change from baseline in femur length (cm)

    Time frame: 6 and 12 months

  16. Change from baseline in arm span proportionality (arm span/height ratio)

    Time frame: 6 and 12 months

  17. Change from baseline in upper segment/lower segment ratio

    Time frame: 6 and 12 months

  18. Change from baseline in elbow extension

    Time frame: 6 and 12 months

07

Study locations

25 of 25 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Jan 2030, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 24, 2025
StartActual
Mar 4, 2025
Primary completionEst.
Jan 2030
CompletionEst.
Jun 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: A•••@tyra.bio · •••4805→t•••@tyra.bio · •••5633. See the current contact
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Contact Study contact changed: A•••@tyra.bio · •••4805→t•••@tyra.bio · •••5633. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06842355
Lead sponsor
Tyra Biosciences, Inc
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 4, 2025
Primary completion
Jan 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Lara Balick
Contact
tyraclinicaltrials@tyra.bio
(929) 792-5633
Doug Warner, MD
study chair · Tyra Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabogratinib

Start the discussion